3-tert-butyl-2,2,6,6-tetramethyl-heptan-4-one | 32836-92-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-tert-butyl-2,2,6,6-tetramethyl-heptan-4-one
• 英文别名: 3-Tert-butyl-2,2,6,6-tetramethylheptan-4-one
• CAS: 32836-92-3
• 化学式: C₁₅H₃₀O
• 分子量: 226.403
• InChiKey: OMMTXEZHZGPTSB-UHFFFAOYSA-N

物化性质

• 沸点：
  242.8±8.0 °C(Predicted)
• 密度：
  0.826±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3-二甲基丁酰氯 生成 3-tert-butyl-2,2,6,6-tetramethyl-heptan-4-one
  参考文献：
  名称：

  Dubois,J.-E.; Lion,C., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1971, vol. 272, p. 1377 - 1380

  摘要：

  DOI：

文献信息

• Hydrogel Prodrugs
  申请人：ASCENDIS PHARMA A/S

  公开号：US20150258205A1

  公开（公告）日：2015-09-17

  The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug.

  本发明涉及一种制备水凝胶的方法，以及通过该方法可获得的水凝胶。本发明还涉及一种制备水凝胶-间隔物共轭物的方法，以及通过该方法可获得的水凝胶-间隔物共轭物，还涉及一种制备载体连结的前药的方法，以及通过该方法可获得的载体连结的前药，特别是提供了能够从载体中控制或持续释放药物的载体连结的前药。此外，本发明涉及使用水凝胶制备载体连结的前药。
• PREVENTION AND TREATMENT OF OCULAR CONDITIONS
  申请人：Ascendis Pharma Growth Disorders Division A/S

  公开号：US20170112939A1

  公开（公告）日：2017-04-27

  The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions.

  本发明涉及含有水凝胶连接的前药的药物组合物，用于治疗、预防和/或诊断眼部疾病，并且包括该药物组合物的眼科设备。
• VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions
  申请人：Ascendis Pharma Ophthalmology Division A/S

  公开号：US20150297740A1

  公开（公告）日：2015-10-22

  The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.

  本发明涉及一种药物组合物，包括一种或多种药学上可接受的辅料和一种VEGF中和前药，该中和前药包括一种VEGF中和生物活性基团，用于治疗一种或多种眼部疾病的方法。
• Mechanisms of epoxidation during ozonation of carbon-carbon double bonds
  作者：Philip S. Bailey、Hank H. Hwang、Chin Yun Chiang

  DOI：10.1021/jo00202a015

  日期：1985.1
• DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT
  申请人：ASCENDIS PHARMA A/S

  公开号：US20150290337A1

  公开（公告）日：2015-10-15

  The present invention relates to apolymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.